Apyx Medical Corp: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Mar 31, 2020 and accepted by EDGAR at Mar 31, 2020, 15:25 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-10-01 to 2019-12-31 | $8.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2019-01-01 to 2019-12-31 | $28.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2019-01-01 to 2019-12-31 | $9.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-10-01 to 2019-12-31 | $5.6m | us-gaap:GrossProfit |
| Gross profit | 12 months2019-01-01 to 2019-12-31 | $19.1m | us-gaap:GrossProfit |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $3.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2019-01-01 to 2019-12-31 | $13.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$20.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2019-01-01 to 2019-12-31 | $8.0k | us-gaap:InterestExpense |
| Income tax | 12 months2019-01-01 to 2019-12-31 | −$130.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$19.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$0.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2019-01-01 to 2019-12-31 | −$0.58 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2019-01-01 to 2019-12-31 | 34,069,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −$18.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $1.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-12-31 | $58.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $76.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $84.7m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $12.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $13.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-12-31 | $71.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000719135-20-000029. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.